Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.
Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals. He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer. He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.
Dr Voliotis has 20 years of experience in the pharmaceutical and biotechnology sector in the US and Europe, with an emphasis on radiopharmaceuticals, and 12 years experience in academic preclinical and clinical research. He has held global drug development roles in large and medium sized pharmaceutical companies and start-up phase companies. He has designed and executed multiple registrational trials in numerous oncology indications, mutiple INDs (investigational new drug applications), preclinical through to first in human trials and has overseen numerous regulatory submissions which have resulted in approvals for four drugs in eight different oncology indications. He was most recently Senior Vice President, Head of Clinical Development of radiopharmaceutical business Convergent Therapeutics. Prior to this he held the same role at oncology company Zentalis Pharmaceuticals (NASDAQ: ZNTL). He previously held a range of development roles with major German multinational pharma company Bayer AG as well as at Japanese company Eisai Inc. Dr Voliotis also recently acted as a Consultant in Oncology Drug Development with Magnesia Partners Consulting LLC, advising on clinical development and regulatory strategy.
Sherin is an accomplished industry leader with many years of experience in pharmaceuticals and biotech. Most recently she was Vice-President – Medical Affairs at POINT Biopharma, where she led the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals. She also provided strategic input and leadership for business development and licensing opportunities. She currently serves as Co-Founder and President at Foundation Amal (Canada-USA), overseeing an executive leadership team of 12 directors and members, who led the successful 2021 cross-border expansion into the USA and spearheaded the development of a successful branding and communication strategy. Previously, she held leadership roles at multinational pharmaceutical and biotechnology companies including Bayer, where she served as Director of Global Medical Affairs Oncology. Dr Al-Safadi holds a PhD in Neurobiology from Concordia University, an MBA in Entrepreneurship & Management from the John Molson School of Business, and a MSc in Pharmacology (oncology drug development) from McGill University.
Vimal joins RAD from Orum Therapeutics where he was Vice President, Head of CMC and Supply Chain. He was responsible for all CMC functions including Process & Analytical Development, Manufacturing, Quality Control, Quality Assurance, Regulatory and Supply Chain. He led the successful manufacture of two ADCs and contributed to filing an IND leading to a Phase-I trial. Prior to Orum, Vimal held roles of increasing responsibility in Process Development and Manufacturing Sciences at several companies, including Actinium Pharmaceuticals where he served as a Director of Process Sciences and Manufacturing. In this role, he led process development and process characterisation of Phase II and Phase III products. Vimal also held a position at Pfizer where he contributed to the refiling of Mylotarg and filing of Besponsa BLAs. He also developed manufacturing processes for various ADCs. Vimal also held roles at Daiichi Sankyo, Progenics Pharmaceuticals and SibTech in various capacities. Vimal has MS in Biotechnology from University of Connecticut and B.S. in Chemical Engineering from Sardar Patel University.
Barbara brings 30 years of industry experience in leading Quality functions for start-ups, manufacturers and commercial companies in Europe, Asia and North America. Barbara’s experience spreads across Contrast Media, Rare Diseases and Radiopharmaceuticals. She brings to RAD experience in developing, managing and improving Quality Systems suitable for product stages from development, through Phase 1, 2, 3 up to launch and commercialization ensuring integrity of data collected and used. She served in Senior Quality roles for Saniona, Progenics Pharmaceuticals and Bracco Imaging .
As acertified Project Management Professional (PMP), and with her strong backgroundin oncology and experience in small, but growing biotech companies, Emily isexcited to join RAD’s team of talented industry professionals and lend herexpertise in leading successful Phase 1 through Phase 3 clinical trials.Most recently she was the former Vice President of Clinical Operations atBiosplice Therapeutics. Emily began her career in the biotech industry in her firstjob as a new graduate from Mount Holyoke College working for a small CRO in theBoston, MA area. She went on to earn her BSN, RN specializing and workingin various critical care and emergency medicine settings until her return toclinical research as a nurse coordinator at Fred Hutchinson Cancer Center in2002. In 2005 she transitioned to the Sponsor side of the table, workingher way through the traditional clinical operations career pathway.
Donna has more than 25 years of experience in the biotech and pharmaceutical industry. An expert in regulatory affairs, she has built and led teams to achieve eleven successful marketing authorizations spanning small molecules, biologic therapies and medical devices. After starting her regulatory career in small biotech companies, she gradually attained positions of increasing responsibility in larger pharmaceutical companies including more recent leadership roles at Ono, Merck Serono and Sanofi. Donna has a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science, M.S. in Pharmaceutics and Pharmaceutical Chemistry and a Ph.D. in Pharmacology from the Ohio State University.
Dr Meszaros is an expert in molecular imaging and radioconjugate development. He is Director of Technical Operations at NanoMab Technology, overseeing non-clinical tracer development, technology transfer and GMP manufacturing of small molecules. Prior to joining NanoMab, Dr Meszaros worked as project leader at BioProbe Ltd, a non-clinical CRO, and as quality control scientist at Theragnostics Ltd. Earlier in his career, he was a research associate at King’s College London, where his research focused on the development of radiolabelled peptide hormones.
Hitesh is an accomplished industry leader in R&D and global project management with over 25 years of experience in pharmaceuticals, radiopharma and biotech sectors. Most recently, he was Global Head of Program Management at Jubilant Pharma, where he led the R&D, strategic and budget planning for all generic & CMO medical devices and radiopharmaceutical programs (pre-clinical through to all clinical phases and commercial launch). He also managed the R&D supply chain at Jubilant. Previously, he held leadership roles at multinational pharmaceutical and biotechnology companies including Abzena, where he served as site head of program management for all linker payloads and ADC, as well as at Sun Pharma where he was managing all brand portfolio programs for oncology and dermatology in the US. Prior to Sun, Hitesh worked at Pharmascience in Montreal, Canada and Ranbaxy Research Labs in India (R&D and regulatory). Hitesh holds a PharmD along with an MBA in Operations Management.
Alison has over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers. She is experienced in the establishment of VC and life science funds, and the portfolio management of assets from private start-ups through to FDA approvals, including involvement in private and public ASX capital raisings. Ms Gartner is a Director of the National Foundation of Medical Research and Innovation, Project Manager at Chimeric Therapeutics and co-founder of Evidentli Pty Ltd.
Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.
Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals. He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer. He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.
.jpeg)
Ms Larkin has a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years experience in senior leadership roles in the industry. She brings a proven track record of leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV. Ms Larkin is currently MD of Hester Larkin Associates Consulting where she consults to diagnostic imaging, pharmaceutical and biotech companies on pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships. She has held several Director and Trustee positions in the UK and Belgium and currently sits on the Board of 3 Charities. She was a business consultant at the Cardiac Imaging Department, Wellington Hospital when it launched the first Electron Beam CT (EBCT) centre. Ms Larkin was previously EMEA General Manager BMS Medical Imaging at Bristol-Myers Squibb and had a 19-year career at DuPont Pharmaceuticals holding several roles in European marketing, European Business development and General Management & VP positions. She was the first non-American female to be appointed as Managing Director & Vice President UK & Ireland for Dupont Pharmaceuticals. For 7 years Ms Larkin also chaired an Industry Working Group on Nuclear Medicine Awareness for ‘Nuclear Medicine Europe-the Industry Association,’ formerly AIPES. With a legal background Ms Larkin has experience in governance, risk, acquisitions, mergers, licensing & divestitures.
Dr Alland is a pediatric hematologist-oncologist with a strong track record in developing oncology drug products. She has held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, where she contributed to multiple successful drug approvals. Dr Alland is currently Chief Medical Officer of PMV Pharmaceuticals, a clinical stage precision oncology company. She serves on the Boards of several biopharmaceutical companies and is a member of the Scientific Advisory Council of Columbia University’s Center for Radiological Research. Previously, she served as Chief Medical Officer of Affimed, a clinical stage immuno-oncology company. Dr Alland obtained her medical degree from New York University School of Medicine, completed her post-doctoral training in pediatrics and hematology/oncology at The Children’s Hospital of Philadelphia,The New York Hospital and Memorial Sloan-Kettering Cancer Center, and served as assistant professor of pediatrics at Albert Einstein College of Medicine. During her academic tenure, she was awarded the James S McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders.
Ian is a highly experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a distinguished C-level career across some of the leading corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012. Prior to that role he was General Manager of ANSTO Radiopharmaceuticals in Sydney Australia, Australia's leading manufacturer of radioisotopes for the nuclear medicine sector. He was also Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at Varian Inc in Palo Alto and Melbourne. Ian was also previously a Director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US.
Noel brings over 25 years of leadership experience in finance, strategy and operations within the biopharmaceutical and biotechnology industries. He has a distinguished track record of building and leading cross-functional teams, driving corporate governance and executing complex financial strategies that support rapid company growth. He is currently serving as CFO at PepGen Inc where he oversaw the company's financial strategy as it undertook a successful IPO in 2022. His leadership was pivotal as PepGen advanced two clinical assets into Phase 1 and 2 trials. Prior to PepGen, he was CFO at EIP Pharma (now CervoMed) where he led the company's IPO planning phase. His career also includes a 15 year tenure at Takeda/Shire PLC where he held various senior roles including VP of R&D Business Operations.
Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’. The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies). Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.
Eric Aboagye is Professor of Cancer Pharmacology and Molecular Imaging at Imperial College London. He is a Fellow of the Academy of Medical Sciences and was awarded the British Institute of Radiology Sir MacKenzie Davidson Medal in 2009. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE Healthcare, GSK, Roche and Novartis.
Dr Hoi Ting obtained his doctorate from the University of Oxford and has built an internationally recognised career as a radiopharmaceutical and nuclear medicine expert. He has worked in both industry and academia including Oxford, Westinghouse, Johnson and Johnson, GE Healthcare and C.A.S. Shanghai National Technology Centre. He was also head consultant in nuclear medicine for CGN Nuclear Technology ( 2016 -2020 ) and a strategic consultant to ITM, a major German nuclear medicine isotopes supplier (2017-2021). He is the founder of NanoMab Technology Limited from which Radiopharm licensed the HER-2, TROP-2, PD-L1 and PTK7 targeting technologies.
Dr Notni is an acknowledged authority in the field of integrins and nuclear medicine. Until recently he was Professor at the Technical University of Munich where his research interests included radiometal complexes for nuclear imaging and therapy, MRI contrast agents, as well as preclinical evaluation and clinical translation of innovative radiopharmaceuticals in particular integrins. For his research, he received several awards, “Radiopharmaceutical Council Young Investigator Award, 1st Prize” of the Society of Nuclear Medicine (2011) and the Innovation Prize in Medicinal and Pharmaceutical Chemistry awarded by the Gesellschaft (DPhG) (2013). In 2016, he received the EANM Springer Prize for the most cited paper in EJNMMI Research, and in 2017, the Georg von Hevesy Prize from the Deutsche Gesellschaft fur Nuklearmedizin (DGN).
Dr Ulmert obtained his medical degree at Lund University in Sweden. Currently at UCLA, he began a Postdoctoral Fellowship at Memorial Sloan Kettering in 2010 and has served as a Senior Research Scientist in the Medical Pharmacology Program and as the Technical Director for the Ludwig Center for Cancer Immunotherapy since 2014. Dr Ulmert’s clinical research is focused on the study of risk factors and biomarkers related to clinically diagnosed prostate cancer and definitive end-points in non-screened cohorts. The overarching goal is to apply these specific tissue targeting vehicles for multimodal molecular imaging strategies, as well as for carriers of therapeutic agents.
Dr Hurvitz is Professor of Medicine at UCLA, co-director of the Santa Monica-UCLA Outpatient Oncology Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Centre at UCLA and Director Breast Oncology. She earned her MD from the University of Southern California and served her internship/residency at UCLA. She received board certification in internal medicine, hematology and medical oncology. Dr Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specialising in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.
Dr. Brady-Kalnay is a professor and distinguished faculty researcher in the department of Molecular Biology & Microbiology, Neurosciences and Pathology at Case Western Reserve University. She also is a member of the Case Comprehensive Cancer Center. Dr. Brady-Kalnay trained in the fields of cell adhesion and signaling. Her research focuses on development and cancer-related signaling via Receptor Tyrosine Phosphatases. She is developing novel molecular diagnostic, prognostic and theranostic imaging agents. Dr. Brady-Kalnay is the founder of NeoIndicate LLC, which is commercializing diagnostic and prognostic technology spun-out of CWRU.
Dr Herrmann is a certified Nuclear Medicine physician who also holds an executive MBA from the University of Zürich. He currently serves as Chair of the Department of Nuclear Medicine at Universitätsmedizin Essen, Germany. Dr Herrmann has 18+ years of exposure to radioligand therapy and has a wealth of experience in early clinical translation of novel radioligand therapy concepts. His previous experience in translating theranostics, ranges from first in human use to contributing to pivotal regulatory approval receiving phase 3 studies. During his previous stints at UCLA and Universitätsklinikum Würzburg he has successfully contributed to building large theranostics programs.
